CN111686175A - Application of kuhuang injection in treating or preventing ocular inflammation - Google Patents
Application of kuhuang injection in treating or preventing ocular inflammation Download PDFInfo
- Publication number
- CN111686175A CN111686175A CN202010541785.9A CN202010541785A CN111686175A CN 111686175 A CN111686175 A CN 111686175A CN 202010541785 A CN202010541785 A CN 202010541785A CN 111686175 A CN111686175 A CN 111686175A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- pharmaceutical composition
- ocular inflammation
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
- A61K36/855—Clerodendrum, e.g. glorybower
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of a pharmaceutical composition in preparing a medicament for improving eyesight and relieving pain or treating and preventing ocular inflammation, wherein the pharmaceutical composition comprises 800-850 parts by weight of oriental wormwood, 800-850 parts by weight of Chinese thorowax root, 230-290 parts by weight of radix sophorae flavescentis, 300-350 parts by weight of rheum officinale and 600-650 parts by weight of folium isatidis. The inventor finds that the pharmaceutical composition according to the embodiment of the invention can be effectively used for improving eyesight, relieving pain or treating and preventing ocular inflammation through clinical experiments, and has low recurrence rate.
Description
Technical Field
The invention relates to the field of medicines, in particular to application of a pharmaceutical composition in preparation of medicines, and more particularly to application of a kuhuang injection in treatment or prevention of ocular inflammation.
Background
The traditional Chinese medicine considers that the conjunctivitis is formed by brewing the conjunctivitis due to wind-heat attacking the lung, liver fire flaming up or internal heat and dampness attacking the interior due to damp-heat accumulation of spleen and stomach, stagnated venation, and qi stagnation and blood stasis. In the etiology and principal symptoms, "examination of Yao letter" (written): the patients with acute itching have no barrier, but have non-uniform sources of diseases, itching caused by wind pathogen, pathogenic annealing, qi and blood circulation, and smooth and itchy veins. The spleen meridian is damp-heat, qi stagnation and blood circulation retardation, the internal manifestation of miliaria, granular gold beads, pus discharge, pain and pain due to sand, and spleen pain. Zhang Shi Yi Neng seven orifices notes: "itching is intolerable, but not always small, wind is the time of spring, so the spring becomes worse. Itching due to wind, lingering dampness, swelling of eyelids due to toxic pathogen, and conjunctival congestion. The essential formula of the medical gold appraisal and the ophthalmology heart method: the term "miliaria" refers to a yellow and soft superficial sore, which is caused by wind-heat in the spleen.
Ku Huang injection has the actions of clearing heat, promoting diuresis, soothing liver and relieving jaundice. Can be used for treating retention of damp-heat in the body, bile overflow, jaundice, hypochondriac pain, debilitation, anorexia, etc.; patients with icteric viral hepatitis with the above symptoms.
The new application of the kuhuang injection needs to be further developed.
Disclosure of Invention
The present invention is directed to solving, at least to some extent, one of the technical problems in the related art.
In a first aspect of the present invention, the present invention provides a use of a pharmaceutical composition for preparing a medicament for improving eyesight, relieving pain or treating and preventing ocular inflammation, the pharmaceutical composition comprising 800 to 850 parts by weight of oriental wormwood, 800 to 850 parts by weight of chaulmoogra, 230 to 290 parts by weight of sophora flavescens, 300 to 350 parts by weight of rhubarb, and 600 to 650 parts by weight of isatis leaf. The inventor finds through clinical experiments that the pharmaceutical composition according to the embodiment of the invention can be effectively used for improving eyesight, relieving pain or treating and preventing ocular inflammation, has a low recurrence rate, and has a significantly reduced treatment cost compared with the pharmaceutical composition used in the prior art, such as a toxic heat removing injection, on the premise of the same treatment course.
According to an embodiment of the present invention, the above-mentioned use may further include at least one of the following additional technical features:
according to an embodiment of the invention, the ocular inflammation is conjunctivitis.
According to an embodiment of the invention, the ocular inflammation is allergic conjunctivitis. The inventors have found that the therapeutic composition according to the embodiments of the present invention is particularly effective in treating or preventing allergic conjunctivitis.
According to a specific embodiment of the present invention, the pharmaceutical composition comprises 833.3 parts by weight of oriental wormwood, 833.3 parts by weight of bupleurum falcatum, 266.7 parts by weight of sophora flavescens, 333.3 parts by weight of rheum officinale and 625 parts by weight of isatis leaf.
According to an embodiment of the invention, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
According to an embodiment of the invention, the pharmaceutical composition is in the form of an injection, a smoke or a dressing.
According to an embodiment of the present invention, the pharmaceutical composition is a kuhuang injection. In clinical experiments, the inventor adds a proper amount of water into the Kuhuang injection to boil, pours the liquid medicine into a thermos bottle/water bottle when the liquid medicine is hot, aims the affected eye at the bottle mouth, fumigates the liquid medicine by using the vapor of the liquid medicine, dips the liquid medicine into sterilized cotton or sterilized gauze when the temperature of the liquid medicine is proper, washes the affected eye (or applies the eye), and obviously improves the allergic conjunctivitis of a patient after 1 week of continuous use.
Additional aspects and advantages of the invention will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the invention.
Detailed Description
The following describes embodiments of the present invention in detail. The following described embodiments are exemplary and are intended to be illustrative of the invention and are not to be construed as limiting the invention.
The terms "first", "second" and "first" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one such feature. In the description of the present invention, "a plurality" means at least two, e.g., two, three, etc., unless specifically limited otherwise.
The invention will now be described with reference to specific clinical trials, it being understood that these examples are illustrative only and are not intended to limit the invention in any way.
And (3) clinical trials:
1. the conjunctivitis patients are collected by the academy of TCM in the Wuxi city from 2017 to 2019 for 120 cases in total.
2. The above patients had the following signs:
(1) symptoms are: itching eyes, foreign body sensation and conjunctival sac secretion increase; most allergic conjunctivitis patients complain of eye itching, and a few patients complain of foreign body sensation; the secretion of the allergic conjunctivitis conjunctival sac mainly takes white mucous secretion as the main part; pediatric patients may appear as eye rolls or frequent blinks. Conjunctival congestion is the most common sign of allergic conjunctivitis, with varying degrees of conjunctival edema. Conjunctival papillae is one of the signs of allergic conjunctivitis.
(2) Physical signs: at least one of conjunctival congestion, conjunctival papilla, and corneal specific lesion.
Observation indexes are as follows: the patients' eye itching, nipple, follicular change and the change of the essential substances are observed.
The above collected conjunctivitis patients are all allergic conjunctivitis patients by diagnosis.
3. Method of administration
The doctor opens one box at a time, or fumigates or applies.
The use method comprises the following steps: boiling the injection with appropriate amount of water, pouring the hot medicinal liquid into thermos bottle or water bottle, directing the affected eye to the bottle mouth, fumigating with medicinal liquid steam, and dipping medicinal liquid with sterilized cotton or sterilized gauze when the medicinal liquid temperature is appropriate, and washing the affected eye (or applying onto eye) with a basic treatment course of 1 week.
3. Treatment criteria were:
and (3) curing: the itching of the eyes is completely disappeared, the conjunctival congestion and edema are resolved, and conjunctival sac secretion and palpebral papilla follicular disappear;
the effect is shown: the symptoms and physical signs are obviously relieved, and most of nipple follicles are removed;
improvement: the symptoms of itching of eyes, red lacrimation, burning sensation, photophobia and the like are improved, and the number of palpebral conjunctiva papillae and follicular orifices is reduced by 50 percent;
and (4) invalidation: no change in symptom signs.
4. The experimental results are as follows:
as a result: the main symptoms of 96 cases in 120 cases are relieved after three days of fumigation, the main symptoms disappear after 7 days of continuous fumigation treatment, the clinical cure is realized, 16 cases are effective after 7 days of continuous fumigation treatment, 4 cases are improved after 7 days of continuous fumigation treatment, 4 cases are ineffective after 7 days of continuous fumigation treatment, and the total effective rate reaches 97 percent after 7 days of continuous fumigation treatment. In the fumigation treatment process, patients complain about very relaxed and comfortable eyes, and the clinical verification treatment method is simple and effective and has no toxic or side effect; is worthy of clinical popularization and application.
5. Typical cases of severe illness:
in Qin and Yi, women in age 33, the disease course is 2 years, manifesting as foreign body sensation in both eyes, increased secretion and blurred vision. The effect is not obvious when the antibiotic eye drops are used for a plurality of times in an external hospital. The doctor is seen 6 months in 2018, the bitter yellow injection is given for fumigation treatment, the disease is improved after 7 days of continuous fumigation treatment, the symptoms disappear after 30 days of treatment, and the disease does not relapse after 1 year of follow-up visit.
Lu Yi, women, 53 years old, the course of disease is 6 years, which shows that the eyes are repeatedly conjunctival congestion and foreign body sensation, the doctor visits 8 months in 2018, the bitter yellow injection is given for fumigation treatment, the effect is obvious after 7 days of continuous fumigation treatment, the symptoms disappear after 21 days of treatment, and the disease does not relapse after 1 year of follow-up visit.
Miao, male, age 41, with a disease course of 4 days, manifests as decreased binocular vision and increased secretions. The doctor visits 7 months in 2019, the bitter yellow injection is given for fumigation treatment, the effect is obvious after 7 days of continuous fumigation treatment, and the symptoms disappear after 14 days of treatment. Follow-up was not to date recurrent.
Zhangqi, female, 18 years old, with a disease course of 3 months, manifested as redness and burning of conjunctiva of both eyes. The doctor visits 5 months in 2019, the bitter yellow injection is given for fumigation treatment, the disease is improved after 7 days of continuous fumigation treatment, and the symptoms disappear after 30 days of treatment. Follow-up was not to date recurrent.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (7)
1. The application of a pharmaceutical composition in preparing a medicament for improving eyesight and relieving pain or treating and preventing ocular inflammation comprises 800-850 parts by weight of oriental wormwood, 800-850 parts by weight of Chinese thorowax root, 230-290 parts by weight of lightyellow sophora root, 300-350 parts by weight of rhubarb and 600-650 parts by weight of indigowoad leaf.
2. The use according to claim 1, wherein the ocular inflammation is conjunctivitis.
3. The use according to claim 1, wherein the ocular inflammation is allergic conjunctivitis.
4. The use of claim 1, wherein the pharmaceutical composition comprises 833.3 parts by weight of oriental wormwood, 833.3 parts by weight of bupleurum falcatum, 266.7 parts by weight of sophora flavescens, 333.3 parts by weight of rhubarb and 625 parts by weight of isatis leaf.
5. The use according to claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
6. Use according to claim 1, wherein the pharmaceutical composition is in the form of an injection, a smoke or a dressing.
7. The use according to claim 6, wherein the pharmaceutical composition is a kuhuang injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010541785.9A CN111686175A (en) | 2020-06-15 | 2020-06-15 | Application of kuhuang injection in treating or preventing ocular inflammation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010541785.9A CN111686175A (en) | 2020-06-15 | 2020-06-15 | Application of kuhuang injection in treating or preventing ocular inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111686175A true CN111686175A (en) | 2020-09-22 |
Family
ID=72480951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010541785.9A Pending CN111686175A (en) | 2020-06-15 | 2020-06-15 | Application of kuhuang injection in treating or preventing ocular inflammation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111686175A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300565A (en) * | 2021-05-06 | 2022-11-08 | 常熟雷允上制药有限公司 | Application of pharmaceutical composition in treating or preventing autoimmune liver injury |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004560A (en) * | 1998-11-16 | 1999-12-21 | Hsu; Wu-Ching | Nasal spray (drop) for treating fever/cold, and its preparation |
| CN110960601A (en) * | 2019-12-20 | 2020-04-07 | 雷允上药业集团有限公司 | Traditional Chinese medicine composition for treating fat metabolism disorder disease and application thereof |
-
2020
- 2020-06-15 CN CN202010541785.9A patent/CN111686175A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6004560A (en) * | 1998-11-16 | 1999-12-21 | Hsu; Wu-Ching | Nasal spray (drop) for treating fever/cold, and its preparation |
| CN110960601A (en) * | 2019-12-20 | 2020-04-07 | 雷允上药业集团有限公司 | Traditional Chinese medicine composition for treating fat metabolism disorder disease and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 孟青青: "过敏性结膜炎的治疗研究进展", 《中国中医眼科杂志》 * |
| 易磊: "《中医验方大全》", 31 May 2013, 上海科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300565A (en) * | 2021-05-06 | 2022-11-08 | 常熟雷允上制药有限公司 | Application of pharmaceutical composition in treating or preventing autoimmune liver injury |
| CN115300565B (en) * | 2021-05-06 | 2023-06-16 | 常熟雷允上制药有限公司 | Use of pharmaceutical compositions for the treatment or prevention of autoimmune liver injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111544390B (en) | Traditional Chinese medicine preparation for treating meibomian gland dysfunction and/or allergic conjunctivitis, ultrasonic atomization and nano-spray preparation and preparation method | |
| CN111686175A (en) | Application of kuhuang injection in treating or preventing ocular inflammation | |
| CN109700937A (en) | A kind of Chinese prescription for treating herpes simplex keratitis and reduce its recurrence | |
| CN102579991B (en) | Traditional Chinese medicine composition for treating herpes simplex viral keratitis | |
| CN105125630A (en) | Eye drops and preparation method thereof | |
| CN1160091C (en) | Medicine for treating ophthalmopathy | |
| CN103736014B (en) | A kind of Chinese medicine composition for the treatment of hyperplasia of prostate | |
| CN103405609B (en) | Traditional Chinese medicine preparation for treating cataract | |
| CN105012784A (en) | Medicine for treating nasitis | |
| CN110302357A (en) | A kind of external application eyesight-improving health care function Chinese medicine composition and preparation method thereof | |
| CN1394624A (en) | Chinese medicine prescription for curing eye disease and its preparation method | |
| CN107714768A (en) | A kind of Chinese medicine composition for treating interior external opculopathy disease and its preparation method and application | |
| CN112107623B (en) | Traditional Chinese medicine composition for improving meibomian gland function | |
| Jie et al. | Physical therapy modalities of Western medicine and traditional Chinese medicine for meibomian gland dysfunction | |
| Su et al. | A Case Report of Vogt-Koyanagi-Harada Syndrome Treated With the Ancient Formula: Dang Gui Long Hui Wan water decoction | |
| Yang et al. | Research Progress in TCM Treatment of Retinitis Pigmentosa | |
| Gao et al. | Integrated Chinese and Western Medicine for the Treatment of Acne Associated Blepharokeratoconjunctivitis Case 1 | |
| CN105596717A (en) | Traditional Chinese medicine preparation for treating herpes virus keratitis | |
| CN104056068A (en) | Traditional Chinese medicine eye drops for treating chronic conjunctivitis | |
| CN103536708A (en) | Traditional Chinese medicine composition for treating keratoconjunctivitis | |
| CN105055764A (en) | Medicine for treating chronic angle-closure glaucoma | |
| CN104997949A (en) | Traditional Chinese medicine for treating rhinitis and preparation method thereof | |
| LIU et al. | Traditional Chinese herbal medicine ultrasonic atomization combined with bloodletting at Ěrjiān (EX-HN 6) for acute catarrhal conjunctivitis: a randomized controlled trial | |
| CN103977296A (en) | Traditional Chinese medicine oral solution for treating urethritis and preparation method thereof | |
| CN113768977A (en) | Application of violet junction liquid in preparation of medicine for treating dry eye after pterygium operation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200922 |